Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
01 Novembre 2022 - 9:02PM
Business Wire
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing
and commercializing software-based medicines called prescription
digital therapeutics (PDTs), today announced the company will
participate in the Credit Suisse 31st Annual Healthcare Conference
in Rancho Palos Verdes, California. Corey McCann, M.D., Ph.D.,
President and CEO, will represent the company in an analyst-led
fireside chat at 3:15 p.m. Pacific Time on Tuesday, November 8.
A live audio webcast can be accessed by clicking here and will
be made available in the Investors section of Pear’s website at
www.peartherapeutics.com. A replay of the webcast will be available
on Pear’s website for up to 30 days following the live
presentation.
About Pear Therapeutics Pear Therapeutics, Inc., which is
traded on Nasdaq as PEAR, is the parent company of Pear
Therapeutics (US), Inc. Pear is the leader in developing and
commercializing software-based medicines, called prescription
digital therapeutics (PDTs). Pear aims to redefine care through the
widespread use of clinically validated software-based therapeutics
to provide better outcomes for patients, smarter engagement and
tracking tools for clinicians, and cost-effective solutions for
payers. Pear has the first end-to-end platform to discover,
develop, and deliver PDTs to patients and a pipeline of products
and product candidates across therapeutic areas, including the
first three PDTs with disease treatment claims from the FDA. Pear’s
product, reSET®, for the treatment of substance use disorder, was
the first PDT to receive marketing authorization from the FDA to
treat disease. Pear’s second product, reSET-O®, for the treatment
of opioid use disorder, was the first PDT to receive Breakthrough
Designation. Pear’s third product, Somryst® for the treatment of
chronic insomnia, was the first PDT submitted through FDA’s
traditional 510(k) pathway while simultaneously reviewed through
FDA’s Software Precertification Pilot Program. For more
information, visit Pear at www.peartherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101005909/en/
Media and Investors: Meara Murphy Senior Director,
Corporate Communications meara.murphy@peartherapeutics.com
Pear Therapeutics (NASDAQ:PEAR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pear Therapeutics (NASDAQ:PEAR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Pear Therapeutics Inc (NASDAQ): 0 recent articles
Plus d'articles sur Pear Therapeutics Inc